$696 Million is the total value of Rhenman & Partners Asset Management AB's 108 reported holdings in Q2 2017. The portfolio turnover from Q1 2017 to Q2 2017 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| VRTX | Vertex Pharmaceuticals Inc | $12,244,000 | +17.8% | 95,013 | 0.0% | 1.76% | +6.9% | |
| FGEN | FibroGen Inc | $4,985,000 | +31.0% | 154,341 | 0.0% | 0.72% | +18.7% | |
| DVA | DaVita Inc | $3,562,000 | -4.7% | 55,000 | 0.0% | 0.51% | -13.7% | |
| RDUS | Radius Health Inc | $3,392,000 | +17.0% | 75,000 | 0.0% | 0.49% | +6.1% | |
| KERX | Keryx Biopharmaceuticals Inc | $3,074,000 | +17.4% | 425,111 | 0.0% | 0.44% | +6.3% | |
| MGNX | Macrogenics Inc | $3,064,000 | -5.9% | 175,000 | 0.0% | 0.44% | -14.6% | |
| CMRX | Chimerix Inc | $2,180,000 | -14.6% | 400,000 | 0.0% | 0.31% | -22.5% | |
| TTPH | Tetraphase Pharmaceuticals Inc | $2,139,000 | -22.4% | 300,000 | 0.0% | 0.31% | -29.7% | |
| BIVV | Bioverativ Inc Reg S | $1,865,000 | +10.5% | 31,000 | 0.0% | 0.27% | +0.4% | |
| PODD | Insulet Corp | $1,796,000 | +19.1% | 35,000 | 0.0% | 0.26% | +7.9% | |
| ACHN | Achillion Pharmaceuticals Inc | $762,000 | +9.0% | 166,000 | 0.0% | 0.11% | -1.8% | |
| RGLS | Regulus Therapeutic Inc | $585,000 | -40.2% | 593,629 | 0.0% | 0.08% | -45.8% | |
| CATB | Catabasis Pharmaceuticals Inc | $441,000 | -11.3% | 310,756 | 0.0% | 0.06% | -20.3% | |
| JPM | JPMorgan Chase & Co | $442,000 | +4.0% | 4,837 | 0.0% | 0.06% | -6.0% | |
| CNCE | Concert Pharm Inc | $420,000 | -18.1% | 30,099 | 0.0% | 0.06% | -25.9% | |
| WFC | Wells Fargo & Co | $405,000 | -0.5% | 7,305 | 0.0% | 0.06% | -9.4% | |
| XOM | Exxon Mobil Corp | $389,000 | -1.8% | 4,823 | 0.0% | 0.06% | -11.1% | |
| ADVM | Adverum Biotechnologies Inc | $385,000 | -7.5% | 154,006 | 0.0% | 0.06% | -16.7% | |
| OCUL | Ocular Therapeutix Inc | $371,000 | 0.0% | 40,000 | 0.0% | 0.05% | -10.2% | |
| OREXQ | Orexigen Therapeutics Inc | $348,000 | -15.7% | 120,000 | 0.0% | 0.05% | -23.1% | |
| HAL | Halliburton Co (Hg Co) | $330,000 | -13.2% | 7,718 | 0.0% | 0.05% | -21.7% | |
| MSFT | Microsoft Corp | $330,000 | +4.4% | 4,793 | 0.0% | 0.05% | -6.0% | |
| BUD | Anheuser-Busch InBev SA ADR spons repr 1 Share | $310,000 | +0.6% | 2,806 | 0.0% | 0.04% | -8.2% | |
| QCOM | Qualcomm Inc | $296,000 | -3.9% | 5,368 | 0.0% | 0.04% | -14.3% | |
| IBM | IBM Corp | $272,000 | -11.7% | 1,766 | 0.0% | 0.04% | -20.4% | |
| TNDM | Tandem Diabetes Care Inc | $187,000 | -33.5% | 234,000 | 0.0% | 0.03% | -38.6% | |
| MRTX | Mirati Therapeutics Inc | $183,000 | -29.6% | 50,000 | 0.0% | 0.03% | -36.6% | |
| THLD | Threshold Pharmaceuticals | $79,000 | -31.3% | 201,537 | 0.0% | 0.01% | -38.9% | |
| OPHT | Ophthotech Corp | $61,000 | -30.7% | 23,920 | 0.0% | 0.01% | -35.7% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-07-11
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| UNITEDHEALTH GROUP INC | 40 | Q3 2023 | 4.0% |
| BIOMARIN PHARMACEUTICAL INC | 40 | Q3 2023 | 5.0% |
| ALKERMES PLC | 40 | Q3 2023 | 3.3% |
| LILLY ELI & CO | 39 | Q3 2023 | 5.8% |
| CVS HEALTH CORP | 39 | Q3 2023 | 3.5% |
| INTRA-CELLULAR THERAPIES INC | 39 | Q3 2023 | 2.4% |
| EDWARDS LIFESCIENCES CORP | 39 | Q3 2023 | 1.7% |
| VERTEX PHARMACEUTICALS INC | 38 | Q3 2023 | 4.3% |
| REVANCE THERAPEUTICS INC | 38 | Q3 2023 | 0.9% |
| ABBVIE INC | 37 | Q3 2023 | 4.4% |
View Rhenman & Partners Asset Management AB's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-14 |
| 13F-HR | 2024-02-13 |
| 13F-HR/A | 2023-11-13 |
| 13F-HR | 2023-11-09 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-12 |
| 13F-HR | 2022-05-13 |
View Rhenman & Partners Asset Management AB's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.